Exciting developments underway in NET cancer landscape.
Exciting developments underway in NET cancer landscape.

NEW CEO LOOKS
TO FUTURE

NETRF welcomes Elyse Gellerman, MHS, to her new role as Chief Executive Officer after serving as Senior Administrative Officer. Elyse looks forward to accelerating the search for breakthroughs in NETs with increased collaboration, outreach, and education. (MORE)

ANTICIPATING ITS
U.S. APPROVAL

Peptide Receptor 
Radionuclide Therapy (PRRT)

PRRT treats NETs by converting a cancer cell’s unique characteristics into a welcome mat for a "Trojan Horse" packed with cancer-killing radiation. Now available in Europe, PRRT may soon be approved for use in the United States. (MORE)
Research

EXPLORING THE BIRTH OF A NET CANCER CELL

Much about a carcinoid cancer cell remains a mystery. For that reason, NETRF funds research to understand how and why a neuroendocrine cancer cell comes to be. Two Harvard researchers are teaming up to explore important longstanding mysteries. (MORE)

PRRT FOR PANCREATIC NETS

NETRF/NANETS Grant Announced

Brian Untch, MD, Memorial Sloan Kettering Cancer Center, won the 2017 Basic Translational Science Investigator grant for his proposal, “Enhancing Peptide Receptor Radionuclide Therapy in Well-Differentiated Pancreatic Neuroendocrine Tumors." (MORE)

NOVEL IMAGING AGENT FOR NETS

NETRF/ERF Pilot Grant Announced

There is a critical need to develop improved diagnostic tools for non-invasive, early detection of NETs in a broader range of patients. New grant-funded research by Babak Behnam Azad, PhD, Johns Hopkins School of Medicine, will work towards this goal. (MORE)
Awards and Accolades

MEYERSON APPOINTMENT

Matthew Meyerson, MD, PhD, a NETRF-funded researcher, has been appointed as Dana-Farber Cancer Institute's first director of Cancer Genomics and as director of Cancer Genomics at the Broad Institute. In addition to defining the role of CDKN1B in SI-NETS with a NETRF grant, he also helped discover the EGFR mutation in lung cancer. Dr. Meyerson is considered among the most influential scientists in the world according to Thomson Reuters. As a recipient of a 2017 NETRF Accelerator Grant, Dr. Meyerson is currently researching causes of SI-NETs for NETRF. (MORE)
Education and Advocacy

JANUARY 2018 PATIENT/FAMILY CONFERENCES

Join us for free full-day conferences for patients and caregivers. Learn about the latest advances in diagnosis and treatment. Speakers will address nuclear medicine, surgery, and interventional approaches. Plus, attendees will learn how to cope with side effects and symptoms with hands-on approaches to nutrition and wellness. (MORE) 
Saturday, January 21
San Francisco, CA 

Mission Bay Conference Center
1675 Owens St. #251
REGISTER NOW

Saturday, January 28
Houston, TX
Onstead Auditorium
MD Anderson Cancer Center
LEARN MORE
See what you can expect. Watch videos from prior conferences here. 

#LetsTalkAboutNETs

On November 10th, we commemorated World NET Cancer Awareness Day to raise awareness about the disease and alert the public to the need for improved diagnostics, information, care, and research.Please help spread the word about NET cancer. (MORE)
Caring and Sharing

MARK YOUR CALENDARS

Accelerate the effort to cure neuroendocrine cancer with your gift to NETRF on Giving Tuesday, November 28th, an annual way to include charitable giving in your holiday shopping. (MORE)
Shop for everyone on your gift list this holiday season at smile.amazon and Amazon donates to NETRF. 
We are pleased to announce that this eUpdate 
is sponsored by Novartis Pharmaceutical Corporation.
Doctor Database   Patient Groups
Newly Diagnosed   About NETs
DONATE
Facebook Twitter
Contact Us

NET Research Foundation
321 Columbus Avenue, Suite 5R
Boston, MA 02116

(617) 946-1780 | info@netrf.org
The mission of the Neuroendocrine Tumor Research Foundation is to fund research to discover cures and more effective treatments for carcinoid, pancreatic, and related neuroendocrine cancers.

NETRF is a 501(c)(3) organization. All contributions are tax-deductible to the extent allowed by law. To learn more,
view our Audited Financial Statements and IRS Form 990.
powered by emma
Subscribe to our email list.